ストックスクリーナーアプリを入手
12.28
4.96%
0.58
前日終値:
$11.70
開ける：
$12.1
24時間の取引高:
186.22K
Relative Volume:
1.26
時価総額：
$3.70B
収益：
$391.87M
当期純損益:
$-441.45M
株価収益率:
-6.6378
EPS:
-1.85
ネットキャッシュフロー:
$-301.21M
1週間 パフォーマンス:
-5.47%
1か月 パフォーマンス:
-8.08%
6か月 パフォーマンス:
-0.97%
1年 パフォーマンス:
-22.03%
1日の値動き範囲:
$12.02
$12.38
1週間の範囲:
$11.61
$12.89
52週間の値動き範囲:
$9.15
$18.00
Alvotech Stock (ALVO) Company Profile
ALVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
12.28 | 3.70B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | UBS | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | アップグレード | Citigroup | Sell → Neutral |
| 2023-09-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-07 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-06 | ダウングレード | Citigroup | Buy → Sell |
| 2022-07-26 | 開始されました | Citigroup | Buy |
すべてを表示
Alvotech (ALVO) 最新ニュース
Teva and Alvotech gets FDA review acceptance for its proposed biosimilar to Eylea - MSN
Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara - MSN
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US - MSN
Teva, Alvotech Launch SELARSDI, Stelara Biosimilar - Contract Pharma
Teva Pharma and Alvotech launch US biosimilar to J&J’s Stelara - PharmaLive
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - MSN
Teva/Alvotech launch biosimilar for J&J Stelara (TEVA:NYSE) - Seeking Alpha
Teva, Alvotech announces U.S. availability of SELARSDI injection - TipRanks
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara -February 21, 2025 at 06:27 am EST - Marketscreener.com
Teva And Alvotech Announce Selarsdi(TM) Injection Now Available In The U.S. -February 21, 2025 at 06:07 am EST - Marketscreener.com
Teva Pharma and Alvotech launch Stelara biosimilar in US -February 21, 2025 at 06:09 am EST - Marketscreener.com
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - GlobeNewswire
FDA-Approved SELARSDI Launches: What Makes This Stelara® Alternative Different? - StockTitan
Alvotech (NASDAQ:ALVO) Stock Price Down 6.7%Time to Sell? - MarketBeat
Alvotech Eyeing US Aflibercept Biosimilar Approval This Year With FDA Acceptance - News & Insights
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea - MSN
Teva and Alvotech advance biosimilar portfolio in USA - The Pharma Letter
FDA accepts BLA for Alvotech’s Eylea biosimilar AVT06 review - World Pharmaceutical Frontiers
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar - Managed Healthcare Executive
Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea (TEVA:NYSE) - Seeking Alpha
FDA Accepts Alvotech’s Eylea Biosimilar for Review - Contract Pharma
Alvotech’s AVT06 Biosimilar Application Accepted by FDA - TipRanks
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept) - Marketscreener.com
US FDA Accepts Alvotech, Teva's Biologics License Application for Eylea Biosimilar - Marketscreener.com
Alvotech and Teva’s BLA filing for AVT06 accepted by FDA - TipRanks
FDA To Review BLA For Alvotech's Proposed Biosimilar To EyleaQuick Facts - Nasdaq
Alvotech and Teva Pharmaceuticals Announce FDA Acceptance of Biologics License Application for AVT06, a Biosimilar Candidate to Eylea - Nasdaq
Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application - Marketscreener.com
Alvotech and Teva Announce Filing Acceptance of U.S. - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Finansavisen
Alvotech (NASDAQ:ALVO) Coverage Initiated by Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Alvotech (ICSE:ALVO) with Buy Recommendation - Nasdaq
UBS maintains Alvotech stock Buy rating, $18 target By Investing.com - Investing.com Australia
UBS Initiates Coverage of Alvotech (ALVO) with Buy Recommendation - MSN
UBS maintains Alvotech stock Buy rating, $18 target - MSN
Alvotech initiated with a Buy at UBS - TipRanks
23,467 Shares in Alvotech (NASDAQ:ALVO) Bought by Tempus Wealth Planning LLC - MarketBeat
Alvotech (NASDAQ:ALVO) Shares Gap DownHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $748,000 Investment in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech (NASDAQ:ALVO) Shares Gap UpStill a Buy? - MarketBeat
FDA accepts Alvotech, Teva's BLAs for Simponi biosimilars - Drug Store News
Alvotech And Teva Announce Acceptance Of BLA For AVT05, A Golimumab Biosimilar - Marketscreener.com
Short Interest in Alvotech (NASDAQ:ALVO) Rises By 244.2% - MarketBeat
Alvotech (ALVO) 財務データ
収益
当期純利益
現金流量
EPS
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):